Get notified of page updates
Education > XRAY > Breast Cancer

FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you. XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program

How To Use XRAY
Search by Topic Submit an Article for Review

Breast Cancer

21 through 30 of 259

Relevance: Medium-High

View Related Clinical Trials

Topic : Sex and intimacy after breast cancer

Relevance: Medium-High

View Related Clinical Trials

Most relevant for: People with breast cancer or metastatic breast cancer in sexual or intimate relationships and their partners

A breast cancer diagnosis and treatment can affect relationships with romantic partners. This review highlights two studies that looked at how people with breast cancer and their partners are affected, how they cope, how best to communicate with each other and how to talk with healthcare providers about concerns related to cancer and sexuality. (Posted 8/8/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Study : Progestin birth control may slightly increase breast cancer risk

Relevance: Medium-High

Strength of Science: High

Research Timeline: Post Approval

Most relevant for: People who are using or have recently used birth control containing only the hormone progestin

Different types of birth control carry different cancer risks. Birth control using the hormone progestin slightly increases the risk of breast cancer during use and for a few years after use. (Posted 7/10/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Study : Breast cancer disparities among the LGBTQ+ community

Relevance: Medium-High

Strength of Science: High

View Related Clinical Trials

Most relevant for: People belonging to the LGBTQ+ community

This study looked at differences in breast cancer treatment outcomes among people from the LGBTQ+ community.  (Posted 6/28/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Guideline : What is breast density and why does it matter?

Relevance: Medium-High

Most relevant for: People who have mammograms

New FDA guidelines for mammograms will go into effect by September 2024. Current FDA guidance requires hospitals and breast centers to give people information about their breast density with their mammogram results. By September 2024, mammogram providers will need to relay to patients who have dense breast that they should discuss the need for additional imaging. This article provides an overview of what breast density means and why it matters. (Posted 6/8/23)

Este artículo está disponible en español.

Read More

Relevance: Medium

Topic : Impact of new laws on cancer treatment during pregnancy

Relevance: Medium

Most relevant for: People who have cancer who are pregnant

The U.S. Supreme Court ruled in 2022 that abortion is no longer a protected right under the Constitution.  This landmark decision leaves regulation of abortion to the states. Cancer treatment during pregnancy may now be impacted in states that have abortion bans or limitations. (Posted 5/31/23)

Este artículo está disponible en español.

Read More

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Article : A food lover’s decision to remove her stomach highlights difficult decisions around cancer risk

Relevance: High

Quality of Writing: High

View Related Clinical Trials

Most relevant for: People with a CDH1 mutation or a family history of stomach cancer

National Public Radio reporter Sáša Woodruff shares her story of learning about her CDH1 mutation and making a decision about risk-reducing surgery. Mutations in the CDH1 gene significantly increase a person’s risk of stomach and breast cancers. Woodruff’s personal essay describes the psychological challenge of making decisions about risk-reducing surgeries and draws attention to a lesser-known mutation linked to hereditary cancer. (Posted 5/17/23)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Study : Breast cancer outcomes improved with CDK4/6 inhibitor treatment

Relevance: High

Strength of Science: Medium-High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with HR-positive HER2-negative advanced breast cancer

A study showed that people with metastatic breast cancer who took an oral drug known as a CDK4/6 inhibitor combined with hormone therapy did better than people who took hormone therapy alone. The drug combination improved the length of time before cancer worsened or returned. After six years of treatment, people who took this drug combination lived longer compared to those who took hormone therapy alone. (Posted 4/5/23)

Este artículo está disponible en español.

Read More

Relevance: Medium

Strength of Science: Medium

Research Timeline: Animal Studies

View Related Clinical Trials

Study : Weight may affect breast cancer risk in women with an inherited BRCA mutation

Relevance: Medium

Strength of Science: Medium

Research Timeline: Animal Studies

View Related Clinical Trials

Most relevant for: People with an inherited mutation in BRCA1 or BRCA2 concerned about their breast cancer risk

A study that looked at normal breast cells from women with an inherited BRCA mutation found more DNA damage among women who were overweight (based on a measurement known as body mass index) than those who were not overweight. The results suggest that maintaining a lower weight may reduce breast cancer among this high-risk population. (Posted 3/30/23)

Este artículo está disponible en español.

Read More

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Study : New oral drug treatment for some advanced breast cancer

Relevance: High

Strength of Science: High

Research Timeline: Post Approval

View Related Clinical Trials

Most relevant for: People with HR-positive, HER2-negative advanced breast cancer

The FDA has approved a new oral drug called Oserdu for the treatment of HR-positive, HER2-negative advanced breast cancer. A blood test was also approved to help doctors identify patients who would benefit most from this new treatment. (Posted 3/20/23)

Este artículo está disponible en español.

Read More

Relevance: Medium-High

Strength of Science: Medium-High

Study : Systemic racism may delay breast biopsy for Black and Asian people

Relevance: Medium-High

Strength of Science: Medium-High

Most relevant for: People who have had an abnormal mammogram

Black and Asian people are more likely to have to wait more than 90 days between an abnormal mammogram and a biopsy compared to white people. After accounting for other factors, the authors conclude that these disparities may be due to systemic racism. (Posted 3/8/23)

Este artículo está disponible en español.

Read More

This Portal Sponsored By:

Centers for Disease Control